Latest news and press releases about Codexis, Inc. (CDXS): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening.
Price
| Price | $1.34 |
| Market Cap | $144M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.70 |
| EV / EBITDA | -9.37 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -74.36% |
| Return on Invested Capital | -22.69% |
| Return on Assets | -25.59% |
| Gross Margin | 83.71% |
| Operating Margin | -31.23% |
| Net Margin | -39.55% |
Related companies: ARMP · CCCC · GNFT · IMDX · IPHA · IVVD · OABI
Explore sector: Healthcare · Biotechnology
More sections of CDXS: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks